Hangzhou Innogate Pharma

Innogate Pharma is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses primarily on two major therapeutic areas: metabolic diseases, particularly Type 2 diabetes, and oncology, with a focus on hormone-driven cancers like breast and prostate cancer. Their lead program, IG-101, is a novel glucokinase activator designed to improve glucose homeostasis in diabetic patients. Innogate leverages its expertise in medicinal chemistry to develop next-generation degraders and modulators, aiming to address unmet medical needs in the global healthcare market.